Hisamitsu Pharmaceutical Co., Inc. — Cyborg Score 5/10

Mixed
Pharmaceutical Manufacturing & OTC Healthcare Products

Strategic Profile

The company operates a single business segment focusing on medical and general pharmaceuticals both in Japan and overseas, marketing drugs under the Salonpas, Nobinobi/Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs. As of February 19, 2026, Hisamitsu Pharmaceutical operates as a subsidiary of Taiyo Kosan Co., Ltd. The company maintains a strong position in OTC pain relief with established brand recognition globally.

Cyborg Score Rationale

Trailing net profit margin sits at 11.8%, compared with 13.9% a year earlier, with critics highlighting that softer profitability weakens the case for a premium valuation. The company's 4.4% forecast revenue growth and 0.3% forecast earnings growth trail broader JP market expectations, and paying a 22.6x P/E versus 17x for the industry raises questions when earnings growth is only forecast at 0.3%.

Top Insights

  • Q3 2026 results showed revenue of ¥39,571 million with net profit margins improving from a year ago
  • FY 2026 results reported trailing 12-month revenue of ¥163.0b, moving from ¥156.0b a year earlier, while EPS declined from ¥295.58 to ¥268.55
  • As of March 20, 2026, the company is trading at a 237% premium with a market cap of ¥423.01B and 70.05M shares outstanding
  • Salonpas® has been recognized as the world's No. 1 OTC topical analgesic patch brand for nine consecutive years as of 2025

Named Competitors

  • Voltaren — Diclofenac-based topical pain relief
  • Bengay — Menthol-based muscle and joint pain relief
  • Thermacare — Heat-activated pain relief wraps

Recent Developments

  • (April 2026) FY 2026 full-year results reported with fourth quarter revenue of ¥48.5b and margin compression to 11.8% from 13.9% year-over-year
  • (March 2026) Stock trading at ¥6,039.00 with market cap of ¥423.01B and P/E ratio of 24.41
  • (February 2026) Became a subsidiary of Taiyo Kosan Co., Ltd. as of February 19, 2026

Open the full interactive Hisamitsu Pharmaceutical Co., Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →